Key Highlights

● Kairos Pharma's ENV-105 antibody, designed to reverse prostate-cancer drug resistance, has produced an 86% clinical-benefit rate in a nine-patient interim analysis. With roughly $3.7 million in cash and a going-concern warning on the books, the clinical-stage company faces a narrow runway as it awaits fuller Phase 2 data and digests a new lung-cancer asset.

● Kairos held cash of approximately $4.5 million at December 31, 2025, declining to roughly $3.7 million as of March 31, 2026, its most recently reported quarter-end.

● The cash position and going-concern disclosure raise real questions about funding the trial to completion without further dilutive financing, and the headline efficacy figures come from a small interim analysis.

● Investors should watch for expanded enrollment and additional interim data from the ENV-105 prostate cancer trial.

Kairos Pharma, Ltd. (NYSE American: KAPA), a Los Angeles-based clinical-stage biopharmaceutical company, has spent the past year promoting interim results from a small Phase 2 trial testing its lead antibody, ENV-105, alongside the approved prostate-cancer drug apalutamide (marketed as Erleada). Company press releases dated September and October 2025, and reaffirmed in November and December 2025, cite an "86% clinical benefit rate" and a median progression-free survival of roughly 13 to 13.7 months in patients with metastatic castration-resistant prostate cancer who had grown resistant to hormone-targeted therapy. The figures are real, as disclosed by the company, but they rest on an interim readout of just nine evaluable patients, a detail investors should weigh carefully against Kairos's thin balance sheet and a fiscal 2025 annual report that flagged substantial doubt about its ability to continue as a going concern.

What happened

Beginning September 18, 2025, Kairos issued a series of shareholder updates on its Phase 2 trial of ENV-105 combined with apalutamide in metastatic castration-resistant prostate cancer (mCRPC), a study enrolling at Cedars-Sinai Medical Center, City of Hope, and the Huntsman Cancer Institute. The company reported that among nine evaluable patients, 86% showed "clinical benefit," defined as remaining progression-free for at least four months, with half of responders progression-free beyond one year. Seven of nine evaluable patients also showed a PSA decline from baseline. Kairos presented an updated version of this data at the European Society for Medical Oncology (ESMO) congress on October 20, 2025, and referenced it again in a November 4, 2025 shareholder letter and a December 17, 2025 release touting a Clinical Trials Arena industry award. The company said no dose-limiting toxicities or Grade 3/4 treatment-related adverse events had been observed to date. Separately, in February and March 2026, Kairos signed a term sheet and then a binding agreement to acquire exclusive worldwide rights to CL-273, a pan-EGFR small-molecule inhibitor for EGFR-mutant non-small-cell lung cancer (NSCLC), and a second asset, CL-741, from OrbiMed- and Torrey Pines-backed Celyn Therapeutics; specific payment terms were not disclosed.

Why the development matters

An 86% clinical-benefit rate would be notable if confirmed in a larger, controlled population, particularly among heavily pretreated mCRPC patients who typically progress within a few months on second- or third-line hormonal therapy. But the trial is open-label, single-arm, and interim, and reported patient counts have varied slightly across disclosures, one release described eight of ten enrolled patients completing the interim analysis (two withdrew for unrelated reasons), while later releases cite nine "evaluable" patients, a discrepancy worth noting. No independent, peer-reviewed publication of the data was identified as of this writing; the company has said it intends to publish safety and efficacy findings in a "high-impact journal" during 2026.

Company and product background

ENV-105 (also called ENV105) is a monoclonal antibody targeting CD105 (endoglin), a cell-surface protein Kairos says cancer cells upregulate in response to androgen-receptor-targeted drugs (enzalutamide, abiraterone, apalutamide) and EGFR tyrosine kinase inhibitors (osimertinib, erlotinib, gefitinib), contributing to acquired resistance. Notably, ENV-105 targets endoglin, not the apelin/APJ pathway; characterizing it as "apelin-targeting" is not supported by the company's SEC filings or website. The prostate program is in Phase 2, targeting enrollment of up to 100 patients by year-end 2026; a companion Phase 1 trial tests ENV-105 in NSCLC. Kairos also lists earlier-stage programs including KROS101, an immunotherapy candidate, and KROS201, a T-cell therapy for glioblastoma with FDA IND clearance. No ENV-105 program has reached a pivotal or registration trial, and no FDA marketing application has been filed.

Financial position

Per SEC filings, Kairos held cash of approximately $4.5 million at December 31, 2025, declining to roughly $3.7 million as of March 31, 2026, its most recently reported quarter-end. Net cash used in operations was about $3.4 million for full-year 2025 and roughly $1.0 million in the first quarter of 2026 alone. Net losses widened from about $2.6 million in fiscal 2024 to $5.4 million in fiscal 2025, with a further $1.7 million loss in the first quarter of 2026. The fiscal 2025 Form 10-K, filed March 31, 2026, included an auditor's going-concern paragraph, which the company also disclosed under NYSE American listing rules. Shares outstanding stood at 21,411,198 as of March 31, 2026. Two Form 424B3 prospectus filings in April 2026 indicate registered share issuances that could add to dilution; proceeds were not detailed in available filings. Based on the Q1 2026 burn rate, cash on hand implies roughly three to four quarters of runway absent additional financing, an estimate, not a company projection.

Bull case

If the ENV-105 mechanism holds up in a larger, more mature cohort, a therapy that resensitizes resistant prostate tumors to already-approved hormonal agents could address a real unmet need. The pending CL-273 lung-cancer asset, aimed at a market Kairos estimates at $16.2 billion for EGFR-mutant NSCLC, could diversify the pipeline. A small market capitalization means confirmatory data or a partnership could move the stock meaningfully.

Risk case

The cash position and going-concern disclosure raise real questions about funding the trial to completion without further dilutive financing. The headline efficacy figures come from a small, unblinded interim analysis with inconsistent patient-count reporting, not a peer-reviewed or FDA-reviewed dataset. The CL-273 acquisition's financial terms remain undisclosed, adding funding risk for a company already burning cash faster than it raises it.

What investors should watch next

1. Completion of Phase 2 enrollment (targeted for up to 100 patients by year-end 2026) and any subsequent, larger interim or final readout.

Conclusion

Kairos Pharma's ENV-105 data have generated genuine investor interest, and the reported 86% clinical-benefit rate is consistent across multiple company disclosures reviewed for this article. But the figure rests on a small, early, single-arm interim analysis, not a controlled or peer-reviewed study, and it arrives alongside a going-concern warning and a cash position that, by the company's own quarterly burn rate, may not stretch far without new financing. Investors weighing the story should separate the clinical narrative from the financial one and watch for larger datasets, independent publication, and confirmed financing terms before drawing conclusions.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.